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patients (33%) had second-line chemotherapy (the majority received 
docetaxel) after progression. The median overall survival was 11.0 
months (95% CI=7.4, 14.6) in those patients who received chemother-
apy after brain radiotherapy. Our results show that only a small fraction 
of NSCLC patients presenting with synchronous brain metastases are 
even considered for chemotherapy after WBRT. Although limited by 
the retrospective nature of the study, good performance status (ECOG 
0-2) NSCLC patients with brain metastases who receive chemotherapy 
after brain radiotherapy have response rates and a median survival 
comparable to the general Stage IV NSCLC population. We propose 
that chemonaive NSCLC patients who receive radiotherapy treatment 
for synchronous brain metastases, and maintain an adequate perfor-
mance status, should be considered for chemotherapy and should not be 
routinely excluded from clinical trials involving systemic therapy.
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First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) 
for patients with advanced non-small-cell lung cancer (NSCLC): 
Molecular correlates
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Background: The combination of cisplatin and vinorelbine is a refer-
ence regimen in ﬁrst-line therapy for advanced NSCLC. The correla-
tion between predictive genetic markers and clinical endpoints may 
improve the prediction of treatment success and thereby the tailoring 
of chemotherapy. In this trial, predictive genetic markers of response to 
CDDP/VRL were examined in genomic DNA and cDNA derived from 
tumors and circulating tumors. 
Methods: 238 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC were accrued at 
35 sites between April 2004 and January 2006. Treatment consisted of 
CDDP 75 mg/m2 IV day 1 plus VRL 25 mg/m2 IV or 60-80 mg/m2 oral, 
days 1, 8 every 21 days. DNA samples were collected from primary 
tumors for the assessment of microtubule associated protein 4 (MAP4) 
and from serum for checkpoint forkhead-associated and ring ﬁnger 
(CHFR) methylation. 
Results: Data on 207 p is available. Median age 62 years (38-80); 
males: 84.5%; smokers: 79.2%; PS 0-1: 94.5%; adenocarcinoma, 
48.4% / squamous, 34.2%; stage IIIB: 16.9%, IV: 83.1%. Median 
cycles: 4 (1-12). Hematological toxicities (%p): grade 3/4 neutropenia, 
8.7%/7.7%; grade 3/4 thrombocytopenia, 0.5%/1.0%; grade 3 anemia, 
2.4%. Febrile neutropenia appeared in 12 p (5,3%). Non-hematologi-
cal toxicities (%p): pulmonary grade 3/4, 3.4%/2.4%; nausea/vomiting 
grade 3/4, 7.7%/0.5%; asthenia grade 3, 12.6%; pain grade 3, 5.8%; 
infection grade 3/4, 3.9%/0.5%; neurotoxicity grade 3, 0.5%. Efﬁcacy 
in evaluable population: CR, 2.8%; PR, 30.7%; ORR, 33.5% (95% 
CI, 26.6% to 40.4%); SD, 36.3%. With a median follow up of 6.6 
months, median survival for the whole population was 8.9 months (m), 
progression free survival 5 m, event free survival 4.8 m, 1-year survival 
39.4%.
Conclusions: The tolerability, efﬁcacy and survival results of this trial 
conﬁrm that CDDP/VRL is effective as ﬁrst-line therapy, presenting a 
favourable toxicity proﬁle in p with advanced NSCLC. Complete data 
on genetic markers will be presented.
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A Phase II study of Carboplatin plus Pemetrexed in previously 
treated patients with non-small cell lung cancer (NSCLC)
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Aim: This Phase II study was conducted in order to deﬁne the efﬁcacy 
and safety of Carboplatin-Pemetrexed combination as a second-line 
treatment for NSCLC patients.
Patient and Methods: Twenty six patients with measurable NSCLC 
and PS 0-1 (ECOG scale) who had failed or relapsed after initial 
chemotherapy, received Carboplatin AUC4 and Pemetrexed 350mg/m2 
on day 1 and 15 on up to 6 q28 cycles. Vitamin B12 and folic acid 
supplementation was given. All patients received GCSF for days 3-5 
and 17-19 of cycles. Response to treatment was evaluated by response 
evaluation criteria in solid tumors (RECIST), and toxicity was graded 
according to the National Cancer Institute Common Toxicity Criteria 
version 3.0.
Results: The most common severs hematological adverse events (CTC 
Grade 3,4) was thrombocytopenia in two patients (7.6%), and anemia 
in one (3.85%). Serious non hematological toxicity was onycholyses 
(3.85%), neuropathy (3.85%), stomatitis (3.85%), and fatigue (3.85%). 
The median number of treatment cycles was 4. Fourteen patients (54%) 
received all six cycles. One patient reported as complete responder 
(3.85%), 5 as partial responders (19%) and 4 had stable disease 
(15.4%), with over all response rate of 38.46%. Median time to pro-
gression for 2nd line chemotherapy and overall survival was 6 and 12.6 
months respectively. 
Conclusions: Second line regimen with carboplatin-pemetrexated in 
intensive schedule is well tolerate and effective treatment for resistant 
or relapsed, after initial chemotherapy, NSCLC.
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Effect of taxotere combination with celecoxib on proliferation of 
NSCLC cell
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Objective: To study the effects of Taxotere, Celecoxib and the combi-
nation of both on proliferation and apoptosis of NSCLC cell. 
Methods: Investigate the effect of Taxotere, Celecoxib and the combi-
nation of both on proliferation of NSCLC A549 by MTT assays. Detect 
the change of apoptosis, cell cycle and the expression of COX-2 protein 
using ﬂow cytometry analysis and immunocytochemistry, respectively. 
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Results: Taxotere could inhibit the proliferation of A549 cell by a 
time and dose-dependent manner and the combination with Celecoxib 
(12.5µmol/l, 25µmol/l) could improve the inhibition. After 48h of incu-
bation with Taxotere, the highest inhibitory rate of the cell is 65% and 
the lowest inhibitory rate is 10%. High-dose celecoxib (>50µmol/l) can 
suppress COX-2 gene expression, while positive response was found 
in low-dose celecoxib(12.5µmol/l,25µmol/l) and the combination. 
Celecoxib can increase the percentage of cell in G0/G1 and decrease 
that in S and G2/M. The apoptosis rate of cell increased after Celecoxib 
combined with Taxotere. 
Conclusion: Taxotere could inhibit effectively the growth of A549 cell 
lines in vitro and the combination with Celecoxib could improve the 
inhibition through induceing apopotosis and inﬂuencing the distribu-
tion of cell cycle, but had no signiﬁcant inﬂuence in the expression of 
COX-2 protein.
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A phase II trial of pemetrexed in non-small cell lung cancer 
patients failing previous platinum-based chemotherapy and with/
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Background: Pemetrexed is an effective salvage agent in NSCLC 
patients failing previous chemotherapy. Our aim was to evaluate the 
efﬁcacy of pemetrexed in Chinese NSCLC patients who had failed 
previous platinum-based chemotherapy and had been salvaged with 
tyrosine-kinase inhibitor (TKI) treatment or not. 
Methods: Treatment consisted of pemetrexed 500 mg/m2 intravenous 
infusion on day 1 of every 3 weeks. Standard premedications, including 
vitamin B12, folic acid, and dexamethasone were given.
Results: Between June 2005 and November 2006, 44 patients (pts) 
were enrolled and completed the study. All had been treated with 
platinum-based chemotherapy. Thirty patients had been treated with 
TKI after they failed platinum-based chemotherapy. The present treat-
ment was second-line treatment in 10 pts, and third-line or higher in 
34 pts. Mean age was 62. Median cycles received was 4, and objective 
response rates was 18.2% (8 pts had PR). Treatment-related toxicities 
were mild and few. Grade 3 or 4 haematological toxicities included 
neutropenia in 18.2%, thrombocytopenia in 6.8%, and anemia in 4.5 
pts. Non-haematological toxicities were all less than grade 3. Median 
time to disease progression was 4.4 months and median survival was 
9.1 months. Those received present treatment as second line treat-
ment had a better response than as third line or later treatment (40% 
vs. 11.8%, p=0.043). Previous treatment with TKI or not did not affect 
patient’s response to present treatment (p=0.782) 
Conclusions: This study demonstrated that pemetrexed salvage chemo-
therapy in NSCLC patients who have failed previous platinum-based 
chemotherapy produces a relatively lower toxicity proﬁle, and a better 
compliance and response rate than conventional salvage chemotherapy. 
Use of pemetrexed as second line agent will have better response rate 
than as third line or later treatment. 
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Phase II randomized study of vinorelbine alone or plus cisplatin 
against Chemo-naïve Inoperable Non-small Cell Lung Cancer in 
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Background: Our aim here was to determine whether or not add-
ing cisplatin into vinorelbine treatment is an appropriate regimen for 
chemo-naïve NSCLC in patients aged 70 or older.
Methods: After stratiﬁcation by performance status, patients were 
randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) 
treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intrave-
nous infusion on days 1 and 8 of every 3 weeks (V arm), or vinorelbine 
22.5 mg/m2 intravenous infusion on days 1 and 8, and cisplatin 60 
mg/m2 intravenous infusion on day 1 of every 3 weeks (VP arm). From 
May 2005 to December 2006, 68 patients were enrolled. Sixty-three 
patients went off-study before end of February 2007. Present analysis 
was based on these 63 patients.
Results: There were 29 patients received V treatment and 34 patients 
received VP treatment. There was no statistical signiﬁcant difference in 
clinical characteristics. In all, 104 cycles of V (median, 4 cycles per pa-
tient) and 137 cycles of VP (median, 4 cycles per patient) were given. 
Objective response rates were 17.2% in V and 32.4% in VP (p=0.175). 
Control rates were 51.7% in V and 82.4% in VP (p=0.009). Myelo-
suppression was more common and severe in VP arm. Any grade of 
anemia and neutropenia were signiﬁcantly higher in VP arm (p=0.002 
and 0.018, respectively). Two patients in VP arm suffered from febrile 
neutropenia and one patient died in spite of G-CSF and antibiotic 
treatment. There was only one patient in V arm who had uneventful 
febrile neutropenia. Non-haematological toxicities was mild and all less 
than grade 3, except one patient in VP arm who suffered from grade 3 
renal function impairment and one patient in V arm who had grade 3 
phlebitis. Fatigue sensation was more common and severe in VP arm 
(p=0.031). Median time to disease progression was 2.7 months in V 
arm and 5.2 months in VP arm (p=0.0125). One-year survival rate was 
49.8% in V arm and 45.4% in VP arm.
Conclusions: Adding cisplatin into vinorelbine treatment is feasible in 
elderly patients, and has better disease control rate and longer me-
dian time to disease progression. However, vinorelbine plus cisplatin 
treatment was more toxic than vinorelbine treatment alone in elderly 
patients.
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The effects of NSCLC neoadjuvant therapy on the serum and 
tumor levels of growth factors, apoptosis and invasiveness markers
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Our aim was to evaluate the effect of neoadjuvant therapy and subse-
quent surgical treatment of non-small cell lung cancer (NSCLC) on 
serum markers of tumor growth and expansion: VEGF, TGF-β, bFGF, 
TIMP-1 and apoptosis marker CD95L assessed by Elisa. 24 NSCLC 
patients were evaluated: 12 in stage IIIA. 9-IIB,1-IIA, 1-IB, 1-IA. 
